CVE-2022-37146

Description

The PlexTrac platform prior to version 1.28.0 allows for username enumeration via HTTP response times on invalid login attempts for users configured to use the PlexTrac authentication provider. Login attempts for valid, unlocked users configured to use PlexTrac as their authentication provider take significantly longer than those for invalid users, allowing for valid users to be enumerated by an unauthenticated remote attacker. Note that the lockout policy implemented in Plextrac version 1.17.0 makes it impossible to distinguish between valid, locked user accounts and user accounts that do not exist, but does not prevent valid, unlocked users from being enumerated.

Category

5.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.13%
Third-Party Advisory controlgap.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
http://plextrac.com product
https://www.controlgap.com/blog/a-plextrac-story third party advisory technical description

Frequently Asked Questions

What is the severity of CVE-2022-37146?
CVE-2022-37146 has been scored as a medium severity vulnerability.
How to fix CVE-2022-37146?
To fix CVE-2022-37146, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-37146 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2022-37146 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.